RE: Research report from simplywall.st26 Aug 2023 18:21
What you at least need to understand is that a company's valuation is based on many factors, not just EBITDA and net income.
Of first and foremost importance on AIM and particularly in times like these is a strong balance sheet. Novacyt has that in the extreme with £81.7m cash (prior to acquisition) and £0 debt. This gives them enormous breathing space to turn around those admittedly poor income statement figures and what with Yourgene being the first acquisition there's hope that will start to show through soon.
To keep things simple imagine the dispute goes in neither parties favour... Novacyt now have their own assets, their own portfolio, their own IP, Yourgene's portfolio, assets and IP and around £55m to shift that operational loss into a profit. If a clear change in direction is seen with profitability posted the following year then we'll likely see a 20X price earnings multiplier applied and possibly higher if there's momentum behind it. So all it takes from all the assets and £55+ to invest is to see £10m+ net income that'll give us a £200m+ mcap / 4 times return from here.
Very achievable without even winning the court case outright.